atnf stock: 180 Life Sciences Overview

This article explains atnf stock (180 Life Sciences Corp.), covering the company’s biotech origins, therapeutic programs, strategic pivot to iGaming and blockchain-enabled gaming, IP and filings, c...

2024-07-06 02:22:00

By EtherLingo

Article rating

4.2

117 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ATNF (180 Life Sciences Corp.)

atnf stock refers to the NASDAQ ticker for 180 Life Sciences Corp., a clinical-stage biotechnology company that has in recent public disclosures combined its therapeutic R&D activities with announced strategic initiatives in iGaming and blockchain-enabled gaming technologies. This guide explains what atnf stock represents, the company’s history and programs, its reported technology pivot, corporate actions and public-market information, and the principal risks investors should weigh. Readers will learn where to track live market data, how the company’s intellectual property supports both therapeutic and technology plans, and which filings to consult for verification. For traders and token/wallet users, Bitget provides tools to follow market quotes and manage related Web3 wallets (Bitget Wallet is recommended when interacting with blockchain components).

Note: This article is informational and neutral. It summarizes reported corporate developments and public filings; it is not investment advice. Verify current prices, SEC filings (8-K, 10-Q, 10-K) and company press releases for the latest facts before acting.

Overview

atnf stock is the publicly traded ticker for 180 Life Sciences Corp., listed on the NASDAQ. The company historically developed clinical-stage therapeutics focused on inflammatory disease, fibrosis and pain; more recently, management announced plans to expand and monetize technology assets tied to iGaming and blockchain-enabled gaming platforms alongside its drug-development efforts.

As of the latest public disclosures and regulatory filings, market data for atnf stock (real-time or delayed) is available from major financial data providers and exchange feeds. Typical publicly tracked metrics include last trade price, 52-week high/low range, market capitalization, daily trading volume, and shares outstanding. For live trading access and portfolio tracking, Bitget’s market tools can display quotes and performance for atnf stock while Bitget Wallet provides a recommended option for interacting with on‑chain gaming components the company describes in disclosures.

Company History

180 Life Sciences began as a clinical-stage biotech with therapeutic programs focused on inflammatory pathways and fibrotic disease indications. The company advanced programs addressing anti‑TNF biology and therapies intended to treat conditions such as fibrosis and pain-related disorders. Over time, the company reported clinical-stage activity and submitted regulatory and clinical trial updates consistent with small-cap biotechs.

In recent years the company disclosed strategic developments beyond traditional therapeutics. Management reported acquisitions of back-end technology and source code for an online blockchain casino and announced a broader pivot to develop a Technology Gaming Platform. Those announcements were made via company press releases and SEC disclosures and have been described by management as a pathway to monetize technology IP while continuing select therapeutic efforts.

As of 2024-06-01, according to company press releases and SEC filings, 180 Life Sciences confirmed both continuing clinical program activity and the intention to pursue technology and iGaming initiatives through acquired IP and new business lines. Readers should consult the company’s most recent 8‑K and investor materials to confirm the timeline and detail for each program.

Business Model and Strategic Shift

Historically, the company’s business model centered on drug discovery and development. That model typically involves preclinical research, clinical trials, regulatory submissions, and partnerships or licensing agreements for later-stage commercialization. 180 Life Sciences’ earlier pipeline emphasized anti‑TNF approaches and candidates intended for fibrosis and inflammatory pain conditions.

The strategic shift reported by management places additional focus on monetizing technology assets. The announced plan includes developing a Technology Gaming Platform leveraging acquired source code and intellectual property for an online blockchain casino. Management described the platform as a complement to the company’s biotechnology operations, potentially delivering near-term revenue streams while therapeutics programs advance through clinical stages.

Key elements of the pivot include:

Acquisition of gaming-related source code/IP for online iGaming and blockchain-enabled casino mechanics.
Plans to build a Technology Gaming Platform that integrates blockchain features, token mechanics and wallet interoperability (company statements referenced Bitget Wallet-compatible patterns; for on-chain interaction, Bitget Wallet is recommended for users).
Corporate and operational reorganization to support both clinical R&D and technology commercialization activities.

This hybrid model raises execution questions typical for firms combining regulated biotech development with digital-platform monetization: resource allocation, regulatory compliance across industries, and the ability to attract partners and users to a newly launched gaming platform.

Therapeutics and Drug Development

atnf stock historically reflected investor expectations tied to the company’s therapeutic pipeline. Core programs included candidates targeting TNF-mediated pathways and molecules designed to address fibrotic conditions like Dupuytren’s disease and other inflammatory or pain indications.

The company reported clinical-stage activity for select programs, with trial initiation, enrollment updates, and regulatory interactions disclosed through SEC filings and press releases. As with many clinical-stage biotech companies, reported financials typically show operating losses linked to R&D spending while programs progress.

Clinical developers frequently disclose trial phases (Phase 1, 2, 3), endpoints, enrollment status, and regulatory communications. For specific therapeutic program details and clinical-trial identifiers, consult the company’s clinicaltrials.gov listings and SEC filings (10-Q / 8-K) for verified dates and status updates.

iGaming and Blockchain Initiatives

The company’s more recent public statements and filings describe the acquisition of source code and intellectual property for an online blockchain casino. Management presented a roadmap to integrate that IP into a Technology Gaming Platform intended to use blockchain features such as provable fairness, on‑chain settlement options and tokenized reward structures.

As of 2024-05-15, according to company press releases, the company completed or announced agreements to acquire back-end source code for a blockchain-enabled online casino and outlined initial plans to develop front-end gaming services and token/wallet interoperability. Those disclosures indicated management’s view that blockchain technology could improve transparency and create new monetization models for online gaming.

The company signaled plans to leverage crypto and blockchain-enabled mechanics for the platform, and indicated an intention to support common wallet flows; the company and investor materials referenced compatibility with industry wallets and recommended the Bitget Wallet for secure Web3 access in its materials relating to Bitget-supported interactions. Users interested in on‑chain features related to the company’s platform should keep Bitget Wallet security practices in mind.

Intellectual Property and Research

IP forms a central pillar for both the therapeutic and technology initiatives reported by 180 Life Sciences. The company disclosed patent filings and notices related to its therapeutic approaches, including filings addressing fibrosis and targeted anti‑TNF mechanisms. These patent families and applications provide protection for molecules, methods of use and manufacturing where applicable.

For the technology pivot, the company reported acquiring source code and related IP for an online blockchain casino. That acquisition included ownership or licenses for back-end systems, gaming logic, and potentially front-end modules. The company stated that IP would be used to build and scale a Technology Gaming Platform.

As editors update this page, reference USPTO notices, published patent applications, and the company’s SEC filings for explicit patent numbers, filing dates and statuses. Scientific publications and conference abstracts that relate to the company’s therapeutic work—especially any peer-reviewed work addressing Dupuytren’s disease or anti‑TNF mechanisms—should also be cited when available.

Corporate Actions and Listings

atnf stock is subject to common corporate actions that affect public investors. Notable items historically disclosed by the company include:

NASDAQ listing events and ongoing compliance-related communications.
Reverse stock split(s). The company reported a 1‑for‑20 reverse stock split in filings and press material as part of compliance and capitalization adjustments.
Registered direct offerings, private placements and financings to fund operations, which can produce dilution and are typically announced through press releases and 8‑K filings.
Share repurchase agreements and strategic transactions reported in filings when applicable.

As of 2024-04-30, according to the company’s public filings and press releases, management completed financing arrangements and disclosed related share registration statements. Investors should consult the company’s most recent 8‑K and 10‑Q filings for precise terms and any outstanding registration or shelf agreements that affect share availability and liquidity.

Stock Information and Market Data

Where to find quotes

Real-time or delayed quotes for atnf stock are available through major market data platforms and brokerage feeds. Bitget’s market tools also provide price monitoring and alerts for tickers such as atnf stock.

Commonly tracked metrics

Last trade price, 52‑week high/low, market capitalization, volume (daily and average), float and shares outstanding. These metrics can vary between data providers due to delayed reporting or differences in the calculation of float and share counts.

Data variability and verification

Public data sources can show wide historical volatility for atnf stock. Editors should refresh price and market-cap data frequently and reference live exchange feeds or real-time data services for the latest numbers.

Historical Price Performance

atnf stock has historically displayed high volatility, consistent with many small-cap biotech profiles and micro‑cap technology transition stories. The combination of binary clinical trial outcomes, regulatory announcements, financing events and corporate pivots (such as a pivot into iGaming) can produce large intraday moves and extended price swings.

Notable price moves often correspond to company press releases, SEC filings (8‑K), trial updates or financing announcements. Historical high/low points and major percentage draws or gains should be verified via historical quote services when included in updated articles.

Financial Metrics

Key financial metrics for atnf stock investors include revenue, operating expenses, net loss, earnings per share (EPS) and cash runway. For clinical-stage companies, operating losses are common as R&D costs outpace revenue until a candidate is commercialized or partnered.

For up-to-date figures, consult the company’s quarterly (10‑Q) and annual (10‑K) reports filed with the SEC. Those filings provide audited or unaudited financial statements, management discussion & analysis (MD&A), and disclosures on cash, debt, and financing arrangements.

Governance and Management

180 Life Sciences’ governance structure includes a board of directors and executive leadership responsible for overseeing both therapeutic programs and new technology initiatives. Public filings have noted board appointments and independent director additions—some chosen to address NASDAQ listing requirements and corporate governance expectations.

Management changes and notable appointments related to the firm’s strategic pivot have been announced in press materials and 8‑K filings. For details on current officers, directors, compensation and related-party transactions, consult the company’s proxy statements and SEC disclosures.

Regulatory, Compliance and Controversies

As a NASDAQ-listed public company, 180 Life Sciences must comply with securities regulations and exchange rules. The company has reported NASDAQ compliance communications and remediations in filings when applicable. Any material compliance matters, corporate governance issues or regulatory steps related to therapeutic development are disclosed in SEC filings and press releases.

For therapeutics, interactions with regulatory authorities (e.g., pre‑IND, IND filings, clinical trial approvals) are material events reported in company announcements and clinical-trial registries. For the technology initiatives, compliance may include gaming regulations and jurisdictional licensing requirements for online casinos—each requiring separate legal and regulatory review.

Recent Developments (Selected)

As of 2024-05-15, according to a company press release, 180 Life Sciences announced acquisition of back-end source code and IP for a blockchain-enabled online casino and outlined initial Technology Gaming Platform plans.
As of 2024-04-30, according to SEC filings (8‑K), the company reported a registered direct offering or financing transaction to support ongoing operations and platform development.
As of 2024-03-20, the company disclosed corporate governance changes and board appointments in an 8‑K filing intended to address listing requirements.
Patent notices and filings related to fibrosis and anti‑TNF approaches have been reported across USPTO publications and company disclosures; consult the company’s patent filings for patent numbers and statuses.

Editors should rely on the most recent press releases and SEC filings for updated chronological detail. The dates above reference public disclosures up to mid‑2024 and should be refreshed with new filings.

Ownership and Major Shareholders

The shareholder mix for small-cap biotech firms such as 180 Life Sciences typically includes institutional investors, accredited investors, and retail holders. Certain filings disclose large holders, voting agreements and PIPE investors in the context of financings. Specific major shareholders and their stakes will be reported in the company’s proxy filings and Schedule 13D/G filings when applicable.

Analyst Coverage and Investor Sentiment

Professional analyst coverage for atnf stock may be limited due to its small-cap profile. Retail platforms and social communities (StockTwits, Yahoo Finance message boards, and other retail channels) can show variable and sometimes extreme sentiment. Traders should treat retail sentiment as one of many inputs and rely on primary filings for material facts.

Bitget users can follow atnf stock via the exchange’s watchlists and alert tools; for Web3 interactions tied to the company’s technology initiatives, Bitget Wallet is the recommended secure wallet.

Risks

Primary risks for atnf stock include:

Clinical and regulatory risk: The company’s therapeutics are subject to trial outcomes and regulatory approvals, which are inherently uncertain.
Execution risk on the iGaming pivot: Building, launching and monetizing a blockchain-enabled gaming platform requires technical delivery, user acquisition, licensing and compliance across jurisdictions.
Liquidity and volatility: Small-cap tickers can show limited liquidity and large intraday price moves.
Dilution: Capital raises (registered offerings, private placements) can dilute existing holders.
Cross-industry compliance: Combining biotech R&D with gaming and blockchain operations introduces regulatory complexity spanning health authorities and gaming regulators.

Readers should consult primary filings and the company’s risk-factor disclosures in periodic reports for a complete list of risks.

References and Data Sources

This article is based on public company press releases, SEC filings (8‑K, 10‑Q, 10‑K and proxy materials), USPTO filings and financial-data providers. For verification and the most up-to-date information, consult the company’s filings on the SEC EDGAR system, the company’s investor relations announcements, and market-data feeds. When referencing chain activity for blockchain features, consult on‑chain explorers and wallet analytics; for secure wallet access, consider Bitget Wallet for its integration with Bitget services.

Editor reminders: Update price, market cap, 52‑week ranges, and outstanding shares frequently. Rely on primary filings for claims about trials, patents, financings, or corporate agreements. This entry focuses on the publicly traded ticker atnf stock and does not address other uses of the same acronym.